s 16020-2 has been researched along with elliptinium in 1 studies
| Studies (s 16020-2) | Trials (s 16020-2) | Recent Studies (post-2010) (s 16020-2) | Studies (elliptinium) | Trials (elliptinium) | Recent Studies (post-2010) (elliptinium) |
|---|---|---|---|---|---|
| 20 | 2 | 1 | 135 | 8 | 1 |
| Protein | Taxonomy | s 16020-2 (IC50) | elliptinium (IC50) |
|---|---|---|---|
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.205 | |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | 0.7 | |
| Fibroblast growth factor receptor 3 | Homo sapiens (human) | 0.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atassi, G; Bisagni, E; Burbridge, M; Guilbaud, N; Jan, M; Kraus-Berthier, L; Pierré, A; Rouillon, MH; Saint-Dizier, D; Visalli, M | 1 |
1 other study(ies) available for s 16020-2 and elliptinium
| Article | Year |
|---|---|
In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Blood Cell Count; Bone Marrow; Breast Neoplasms; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Ellipticines; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Leukemia P388; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Tumor Cells, Cultured | 1996 |